ERBB2 and breast cancer: Data from the DESTINY-Breast 12 trial showed substantial and durable overall and intracranial activity with T-DXd in patients with HER-2 positive BC and brain metastasis, irrespective of stable/active baseline brain metastasis [10] (Table 1).